Actively Recruiting
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
Led by Institut Pasteur · Updated on 2025-07-09
92
Participants Needed
4
Research Sites
144 weeks
Total Duration
On this page
Sponsors
I
Institut Pasteur
Lead Sponsor
C
Centre Hospitalier Universitaire de Caen
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
CONDITIONS
Official Title
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults under 60 years old
- Diagnosis of Hidradenitis Suppurativa according to European Dermatology guidelines
- Recurrent inflammation more than twice in the past 6 months in inverse body regions with nodules, sinus tracts, or scarring
- Involvement of axilla, genitofemoral area, perineum, gluteal area, or inframammary area in women
- Presence of nodules, sinus tracts, abscesses, or scarring
- Active HS with at least 1 year duration and 4 or more flares in the previous year
- Clinical severity at Hurley stage 2
- Body mass index (BMI) less than 35
- Written informed consent
- Ability to complete Dermatology Life Quality Index (DLQI)
- Affiliated with the French health system (except French state medical aid beneficiaries)
- Use of active contraception or inability to procreate for men and women of childbearing potential
- Available laboratory blood test within the last 2 months
You will not qualify if you...
- Age under 18 or 60 years and older
- Hurley stage 3 HS
- Previous use of the experimental treatment
- Use of unauthorized drugs for the study within the month before inclusion
- Contraindications to study treatments or excipients such as pregnancy, breastfeeding, allergies to study drugs, wheat allergy, tendinopathy, QT prolongation, bradycardia, heart failure, heart rhythm disturbances, electrolyte disorders, hypokalemia, coagulation disorders, severe liver or kidney dysfunction, porphyria, or required use of NSAIDs for other conditions
- Uncontrolled diabetes (HbA1c above 7%)
- Dysphagia or untreated gastroesophageal reflux or ulcer
- Body mass index (BMI) of 35 or higher
- Immune suppression or inflammatory diseases including gastroenterologic and rheumatologic conditions
- Lactase deficiency, lactose or galactose intolerance
- Malabsorption syndrome
- Living in the same household as another patient
- Under guardianship or curatorship
- Any condition interfering with study evaluation or poor expected adherence
- Participation in another interventional health product research
- Need for repeated antibiotic use (more than 3 times per year) for other chronic diseases than HS
- Alcohol dependence
- Pregnancy, QT prolongation, abnormal lab tests contraindicating study treatments
- Development of hypersensitivity to study products or excipients during the study
- Use of unauthorized drugs during the study according to drug interaction guidelines
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Hôpital de la Timone
Marseille, France
Not Yet Recruiting
2
Centre Médical de l'Institut Pasteur
Paris, France
Actively Recruiting
3
Hopital St Joseph
Paris, France
Active, Not Recruiting
4
CHU de Rouen
Rouen, France
Not Yet Recruiting
Research Team
M
Maïa Delage-Toriel, MD
CONTACT
A
Aude Nassif, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here